The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008
Open accessAbstract
The surveillance of seasonal influenza virus susceptibility to neuraminidase (NA) inhibitors was conducted using an NA inhibition assay. The 50% inhibitory concentration values (IC 50 s) of 4,570 viruses collected globally from October 2004 to March 2008 were determined. Based on mean IC 50 s, A(H3N2) viruses (0.44 nM) were more sensitive to oseltamivir than A(H1N1) viruses (0.91 nM). The opposite trend was observed with zanamivir: 1.06 nM for A(H1N1) and 2.54 nM for A(H3N2). Influenza B viruses exhibited the least susceptibility to oseltamivir (3.42 nM) and to zanamivir (3.87 nM). To identify potentially resistant viruses (outliers), a threshold of a mean IC 50 value + 3 standard deviations was defined for type/subtype and drug. Sequence analysis of outliers was performed to identify NA changes that might be associated with reduced susceptibility. Molecular markers of oseltamivir resistance were found in six A(H1N1) viruses (H274Y) and one A(H3N2) virus (E119V) collected between 2004 and 2007. Some outliers contained previously reported mutations (e.g., I222T in the B viruses), while other mutations [e.g., R371K and H274Y in B viruses and H274N in A(H3N2) viruses) were novel. The R371K B virus outlier exhibited high levels of resistance to both inhibitors (>100 nM). A substantial variance at residue D151 was observed among A(H3N2) zanamivir-resistant outliers. The clinical relevance of newly identified NA mutations is unknown. A rise in the incidence of oseltamivir resistance in A(H1N1) viruses carrying the H274Y mutation was detected in the United States and in other countries in the ongoing 2007 to 2008 season. As of March 2008, the frequency of resistance among A(H1N1) viruses in the United States was 8.6% (50/579 isolates). The recent increase in oseltamivir resistance among A(H1N1) viruses isolated from untreated patients raises public health concerns and necessitates close monitoring of resistance to NA inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The annual impact of seasonal influenza in the US: Measuring disease burden and costs
Molinari, N.-A. M., Ortega-Sanchez, I. R., Messonnier, M. L., Thompson, W. W., Wortley, P. M., Weintraub, E., & Bridges, C. B. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.046 · Cited by 1,722
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
Potier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 815
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Bright, R. A., Medina, M.-J., Xu, X., Perez-Oronoz, G., Wallis, T. R., Davis, X. M., Povinelli, L., Cox, N. J., & Klimov, A. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67338-2 · Cited by 725
Self-citationOral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Isolation of drug-resistant H5N1 virus
Le, Q. M., Kiso, M., Someya, K., Sakai, Y. T., Nguyen, T. H., Nguyen, K. H. L., Pham, N. D., Ngyen, H. H., Yamada, S., Muramoto, Y., et al. (2005) · Nature · doi:10.1038/4371108a · Cited by 693
Bright, R. A. (2006) · JAMA · doi:10.1001/jama.295.8.joc60020 · Cited by 671
Self-citationDeyde, V. M., Xu, X., Bright, R. A., Shaw, M., Smith, C. B., Zhang, Y., Shu, Y., Gubareva, L. V., Cox, N. J., & Klimov, A. I. (2007) · The Journal of Infectious Diseases · doi:10.1086/518936 · Cited by 543
Self-citationEvidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus
Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C., & Webster, R. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/314440 · Cited by 432
Self-citationOseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
Ward, P., Small, I., Smith, J., Suter, P., & Dutkowski, R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki018 · Cited by 428
Monto, A. S., McKimm-Breschkin, J. L., Macken, C., Hampson, A. W., Hay, A., Klimov, A., Tashiro, M., Webster, R. G., Aymard, M., Hayden, F. G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01339-05 · Cited by 364
Self-citationSelection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir
Gubareva, L. V., Kaiser, L., Matrosovich, M. N., Soo‐Hoo, Y., & Hayden, F. G. (2001) · The Journal of Infectious Diseases · doi:10.1086/318537 · Cited by 318
Self-citationMcKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., & Zambon, M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2264-2272.2003 · Cited by 291
Self-citationRecovery of Drug‐Resistant Influenza Virus from Immunocompromised Patients: A Case Series
Ison, M. G., Gubareva, L. V., Atmar, R. L., Treanor, J., & Hayden, F. G. (2006) · The Journal of Infectious Diseases · doi:10.1086/500465 · Cited by 261
Self-citationColman, P. M., Hoyne, P. A., & Lawrence, M. C. (1993) · Journal of Virology · doi:10.1128/jvi.67.6.2972-2980.1993 · Cited by 255
Richman, D. D. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.03.004 · Cited by 216
Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors
Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., et al. (2007) · JAMA · doi:10.1001/jama.297.13.1435 · Cited by 216
Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors
Mishin, V. P., Hayden, F. G., & Gubareva, L. V. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4515-4520.2005 · Cited by 216
Self-citationProlonged Shedding of Multidrug-Resistant Influenza A Virus in an Immunocompromised Patient
Weinstock, D. M., Gubareva, L. V., & Zuccotti, G. (2003) · New England Journal of Medicine · doi:10.1056/nejm200302273480923 · Cited by 207
Self-citationWetherall, N. T., Trivedi, T., Zeller, J., Hodges-Savola, C., McKimm-Breschkin, J. L., Zambon, M., & Hayden, F. G. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.2.742-750.2003 · Cited by 207
Gubareva, L. V., Bethell, R., Hart, G. J., Murti, K. G., Penn, C. R., & Webster, R. G. (1996) · Journal of Virology · doi:10.1128/jvi.70.3.1818-1827.1996 · Cited by 202
Self-citationYen, H.-L., Hoffmann, E., Taylor, G., Scholtissek, C., Monto, A. S., Webster, R. G., & Govorkova, E. A. (2006) · Journal of Virology · doi:10.1128/jvi.00477-06 · Cited by 187
Baz, M., Abed, Y., McDonald, J., & Boivin, G. (2006) · Clinical Infectious Diseases · doi:10.1086/508777 · Cited by 179
Mutations of neuraminidase implicated in neuraminidase inhibitors resistance
Ferraris, O., & Lina, B. (2008) · Journal of Clinical Virology · doi:10.1016/j.jcv.2007.10.020 · Cited by 171
Hampson, A. W., & Mackenzie, J. S. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00705.x · Cited by 164
Yen, H.-L., Ilyushina, N. A., Salomon, R., Hoffmann, E., Webster, R. G., & Govorkova, E. A. (2007) · Journal of Virology · doi:10.1128/jvi.01067-07 · Cited by 162
Position statement: global neuraminidase inhibitor susceptibility network
Zambon, M. C. F. A., & Hayden, F. G. (2001) · Antiviral Research · doi:10.1016/s0166-3542(01)00124-3 · Cited by 155
Wang, M. Z., Tai, C. Y., & Mendel, D. B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3809-3816.2002 · Cited by 152
Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay
Gubareva, L. V., Webster, R. G., & Hayden, F. G. (2002) · Antiviral Research · doi:10.1016/s0166-3542(01)00192-9 · Cited by 149
Self-citationHurt, A. C., Barr, I., Härtel, G., & Hampson, A. W. (2004) · Antiviral Research · doi:10.1016/j.antiviral.2003.11.008 · Cited by 111
Escuret, V., Frobert, É., Bouscambert‐Duchamp, M., Sabatier, M., Grog, I., Valette, M., Lina, B., Morfin, F., & Ferraris, O. (2007) · Journal of Clinical Virology · doi:10.1016/j.jcv.2007.10.019 · Cited by 86
McKimm‐Breschkin, J. L. (2005) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200504020-00004 · Cited by 69
Hayden, F. G., Klimov, A. I., Tashiro, M., Hay, A. J., Monto, A. S., McKimm‐Breschkin, J. L., Macken, C. A., Hampson, A. W., Webster, R. G., Amyard, M., et al. (2005) · Antiviral Therapy · doi:10.1177/135965350501000811 · Cited by 63
Self-citationBaum, E. Z., Wagaman, P. C., Ly, L., Turchi, I. J., Le, J., Bucher, D. J., & Bush, K. (2003) · Antiviral Research · doi:10.1016/s0166-3542(03)00011-1 · Cited by 42
Cited by
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., McGeer, A. J., Neuzil, K. M., Pavia, A. T., Tapper, M. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598513 · Cited by 647
Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005–2009
Shinde, V., Bridges, C. B., Uyeki, T. M., Shu, B., Balish, A., Xu, X., Lindstrom, S., Gubareva, L. V., Deyde, V., Garten, R. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903812 · Cited by 607
Self-citationAntiviral Natural Products and Herbal Medicines
Lin, L.-T., Hsu, W.-C., & Lin, C.-C. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.124335 · Cited by 529
Metadata
- Authors
- Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., & Gubareva, L. V.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-09
- Volume
- 52
- Issue
- 9
- Pages
- 3284-3292
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2128060816
- Cited by
- 480
- References
- 36
- FWCI
- 42.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.